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Abstract
The objective of the research was to evaluate the effectiveness of long-term antiplatelet and hepatoprotective differentiation
therapy in patients with postinfarction cardiosclerosis and co-existent non-alcoholic fatty liver disease in stage of steatosis.
Materials and methods. There were examined 72 patients with stable coronary heart disease functional classes II-III and
co-existent non-alcoholic fatty liver disease in stage of steatosis. All the patients underwent a complete clinical examination;
the functional state of their liver and platelet haemostasis were assessed. All patients received standard therapy the
effectiveness of which was assessed 3 and 6 months after treatment.
Results. The effectiveness of antiplatelet therapy was found to depend on treatment duration, the functional state of the liver
and the scheme of antiplatelet and hepatoprotective differentiation therapy. In particular, 6 months after treatment, a positive
dynamics of platelet haemostasis was observed in all the patients of Group I. However, the target value of its indicators was
achieved in 60.5% of patients. In Group II, the target level of platelet aggregation activity was achieved in 38.3% of patients.
The level of liver enzymes was within the control limits in 52.8% of patients. In 47.2% of patients, however, an increase in
their level was observed, which necessitated the administration of appropriate hepatoprotective therapy.
Conclusions. The developed concept of differentiation treatment of patients with coronary heart disease and co-existent
non-alcoholic fatty liver disease in stage of steatosis envisages the need for monitoring the indicators of platelet haemostasis
and liver function every three months after the administration of antiplatelet therapy with the possibility of its intensification
and the inclusion of hepatoprotective drugs.
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Problem statement and analysis of the
recent research
Coronary heart disease (CHD) remains one of the greatest
challenges facing modern medicine today being the leading
cause of death and disability worldwide [2, 5]. The major
pathogenetic basis for CHD development is atherosclerosis
as well as thrombus formation on the surface affected by
atherosclerosis [11]. In addition to cardiovascular diseases,
hepatobiliary pathology is also a medical and social problem,
since in 60% of cases, liver diseases affect people of working
age [8]. The most common chronic hepatobiliary disease is
non-alcoholic fatty liver disease (NAFLD), the initial manifes-
tation of which is steatosis [7]. Nowadays NAFLD co-exist
with obesity, insulin resistance, dyslipidemia, CHD, type 2
diabetes mellitus and metabolic syndrome as well as plays a
key pathogenetic role in their development [10, 14].
However, the mechanisms by which NAFLD increases
the cardiovascular risk are not fully understood. It is due to
the increase in the formation of atherogenic pro-inflammatory
cytokines and procoagulant factors in the liver affected by
steatosis [6, 9, 16]. In addition, basic mechanisms leading
to NAFLD progression as well as atherogenesis acceleration
include dyslipidemia, insulin resistance, high blood pressure,
oxidative stress, systemic inflammation, adipokine imbalance,
endothelial dysfunction etc. [10]. Furthermore, there are no
data to explain why hepatic steatosis does not develop in all
the patients at high cardiovascular risk and may not always
progress to steatohepatitis and liver cirrhosis. Thus, hepatic
steatosis is considered as a risk factor for atherosclerosis even
in the absence of metabolic syndrome or other cardiovascu-
lar risk factors [14]. Cardiovascular diseases may, in turn,
affect the clinical course of NAFLD thereby increasing the
possibility of its progression to liver fibrosis and cirrhosis [11,
16].
Therefore, the study of common clinical and pathogenetic
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mechanisms involved in CHD and NAFLD occurrence with
the aim of developing a comprehensive and individual ap-
proach to treatment and prevention of such comorbid pathol-
ogy is intensely relevant to modern medicine [4, 17]. Fur-
thermore, the evaluation of the possibility, effectiveness and
safety of using antiplatelet therapy (APT) in stable CHD with
co-existent NAFLD is promising.
The objective of the research was to evaluate the effective-
ness of long-term antiplatelet and hepatoprotective differen-
tiation therapy in patients with postinfarction cardiosclerosis
and co-existent NAFLD in stage of steatosis.
1. Materials and methods of the research
There were examined 72 patients (the average age - 53.7±4.6)
with stable CHD FC I-II and co-existent NAFLD in stage of
steatosis. The control group included 20 apparently healthy
individuals.
The diagnosis of stable CHD was verified according to
the results of electrocardiography, coronary catherization as
well as the presence of myocardial infarction in past medi-
cal history in accordance with the unified clinical protocol
”Stable Coronary Heart Disease” (Order of the Ministry of
Health of Ukraine of 02.03.2016, No 152) [13]. The diag-
nosis of NAFLD was made according to the unified clini-
cal protocol ”Non-Alcoholic Steatohepatitis” (Order of the
Ministry of Health of Ukraine of 06.11.2014, No 826) [12],
the adapted clinical practice guidelines ”Non-Alcoholic Fatty
Liver Disease” [1] in accordance with the clinical practice
recommendations of the European Association for the Study
of the Liver (EASL), the European Association for the Study
of Diabetes (EASD) and the European Association for the
Study of Obesity (EASO) [15].
All the patients underwent a complete clinical examination
(the analysis of complaints, past medical history, life history,
physical examination), electrocardiography, echocardiogra-
phy, coronary catherization, liver ultrasound; the functional
state of their liver and platelet haemostasis were assessed.
The functional state of the liver was assessed by serum
activity of aspartate aminotransferase (AST), alanine amino-
transferase (ALT), gamma-glutamyl transpeptidase (GGTP)
using the spectrophotometric method by means of standard
kits.
Platelet haemostasis was assessed by the indicators of
platelet aggregation activity (the degree of aggregation, the
rate of aggregation, platelet aggregation time, platelet count,
von Willebrand factor) by means of the aggregometer Solar
AP-2110 (Republic of Belarus) using 2.5 µmol/L adenosine
diphosphate according to generally accepted standard proce-
dures [3].
All the patients enrolled in our study adhered to the rec-
ommendations involving lifestyle modification such as diet
therapy and regime of increasing physical activity depend-
ing on the time period after acute coronary syndrome and
exercise tolerance. According to clinical protocols, they re-
ceived standard therapy including beta blockers, long-acting
nitrates, calcium channel blockers, angiotensin-converting-
enzyme (ACE) inhibitors or sartans (if necessary), adjusted
doses of statins and acetylsalicylic acid at a dose of 75 mg
orally once a day. The effectiveness of therapy was assessed
3 and 6 months after treatment.
Depending on the dynamics of changes in the level of
liver enzymes 3 months after treatment, all the patients were
divided into 2 groups: Group I included 38 patients with
normal liver enzyme level; Group II included 34 patients
with elevated liver enzyme level -1.5-2 times higher than the
normal range.
Six months after treatment, in Group I, APT was effective
in 23 cases (subgroup A), while in 15 cases (subgroup B), it
was insufficiently effective. In Group II, APT was effective
for 13 patients with normal liver enzyme level (subgroup A);
APT was found to be insufficiently effective for 13 patients
with normal liver enzyme level (subgroup B); in 10 patients
with elevated liver enzyme level up to 1.5-2 times as compared
to their values observed 3 months after treatment, APT was
insufficiently effective (subgroup C). If APT was insufficiently
effective, it was corrected 3 and 6 months after treatment
and patients with elevated liver enzyme level additionally
underwent hepatoprotective differentiation therapy (Fig.1).
The obtained data were statistically processed using spread-
sheet software Microsoft Excel and an advanced analytics
software package Statistica v. 10.0 StatSoft, USA. A reliable
difference between the mean values was assessed using paired
Student’s t-test. The mean values were presented as (M±m),
where M was the mean and m was the standard error of the
mean. The results were considered statistically significant at
p<0.05.
2. Results of the research and their
discussion
The effectiveness of APT by the indicators of platelet aggre-
gation activity was found to depend on treatment duration, the
functional state of the liver and the scheme of antiplatelet and
hepatoprotective differentiation therapy (Table 1). In partic-
ular, 6 months after treatment, positive dynamics in platelet
haemostasis was observed in all the patients of Group I. How-
ever, the target value of the indicators of platelet aggregation
activity was achieved in 23 (60.5%) patients only. In Group
IA, platelet aggregation time increased by 49.4% as compared
to the basal level and by 26.8% as compared to that observed
3 months after treatment (p<0.05). In Group IB, this indicator
increased by 26.6% as compared to its initial value (p<0.05);
however, it did not reach the level of the control group being
only 7.5% higher as compared to the indicator observed 3
months after treatment (p>0.05).
Six months after treatment, aggregation rate decreased by
28.8% (Group IA) and 14.8% (Group IB) as compared to the
basal level. In Group IA, this indicator reached the level of
the control group, while in Group IB, it was 18.4% higher
(p<0.05). Moreover, the difference between the degree of
aggregation 6 months after treatment and the basal level was
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-9.51 in patients of Group IA and -7.59 in patients of Group
IB.
In patients of Group IA, a six-month treatment resulted in
the decrease in platelet count by 29.7% as compared to their
initial value being 13.1% lower than this indicator 3 months
after therapy (p<0.05). In patients of Group IB, a six-month
treatment resulted in the decrease in platelet count by 23.8%
as compared to the initial values (p<0.05) being only 5.8%
lower than this indicator in the control group (p>0.05). At the
same time, von Willebrand factor decreased by 27.4% (Group
IA) and 18.2% (Group IB) as compared to its initial value
(p<0.05). The difference between this indicator 6 months
after treatment and the basal level was -71.07 in patients of
Group IA, while in patients of Group IB, it was -47.23 only.
In Group II, 6 months after treatment, the target level of
platelet aggregation activity was achieved in 13 (38.3%) pa-
tients only. In Group IIA, platelet aggregation time increased
by 47.0% as compared to its initial value and by 25.5% as
compared to this indicator observed 3 months after treatment
(p<0.05). In Group IIB and Group IIC, platelet aggregation
time increased by 23.8% and 19.2% as compared to the basal
level (p<0.05); however, it did not reach the level of the con-
trol group. Aggregation rate decreased by 27.3% (Group IIA),
19.5% (Group IIB) and 18.8% (Group IIC) as compared to its
basal level (p<0.05). In Group IIA, this indicator reached the
level of the control group, while in Group IIB and Group IIC,
it remained 11.9% and 12.8% higher than that in the control
group (p<0.05). Moreover, the difference between the degree
of aggregation 6 months after treatment and the basal level
was more significant in patients of Group IIA constituting
-8.87 as compared to -6.91 in patients of Group IIB and -6.36
in patients of Group IIC.
In patients of Group IIA, a six-month treatment resulted
in the decrease in platelet count by 27.9% as compared to the
initial values being 13.6% lower than this indicator 3 months
after therapy (p<0.05). In Group IIB and Group IIC, these
changes were less significant - their platelet count decreased
by 22.5% and 19.1% as compared to the basal level (p<0.05);
by 7.2% and 3.1% as compared to the indicator observed 3
months after treatment (p>0.05) that did not correspond to the
level of the control group. Similar tendencies were observed
when analyzing von Willebrand factor. In Group IIA, the
difference between this indicator 6 months after treatment and
the basal level was -67.18 as compared to -51.14 in Group
IIB and -41.14 in Group IIC being 48.1%, 31.8% and 15.3%
lower than this difference 3 months after treatment in Group
IIA, Group IIB and Group IIC, respectively (p<0.05).
The assessment of the functional state of the liver 3 months
after therapy revealed certain features of changes (Table 2). In
38 (52.8%) patients, the level of liver enzymes was within the
control limits. However, in 34 (47.2%) patients, an increase
in their level was observed, which necessitated the admin-
istration of appropriate hepatoprotective therapy (Fig.1). In
patients of Group I, AST and ALT levels were within the
normal range being 7.95 and 3.7% higher than those in the
control group (p>0.05). GGTP level corresponded to that
in the control group being 2.9% lower than its initial value
(p>0.05). However, in patients of Group II, AST and ALT
levels increased by 1.7 and 1.8 times as compared to their
initial values (p<0.05). Moreover, GGTP level increased by
1.6 times as compared to its initial value (p<0.05).
Six months after treatment, the level of liver enzymes in
Group I was stable corresponding to their level in the control
group. In Group IA, AST level was 7.1% lower as compared
to its initial value; in Group IB, it was 2.4% higher than its
initial value (p>0.05). In patients of Group IA, a six-month
treatment resulted in the decrease in ALT level by 10.0% as
compared to its initial value; in patients of Group IB, a six-
month treatment resulted in the decrease in ALT level by 3.3%
as compared to its initial value (p>0.05). In patient of Group
IA and Group IB, GGTP level decreased by 10.2% and 7.6%,
respectively (p>0.05) as compared to its initial value.
In Group II, ambiguous changes in the functional state
of the liver were observed 6 months after therapy. Liver en-
zymes reached the level of the control group in 24 (70.6%)
patients. In 10 (29.4%) patients, there was observed a sig-
nificant decrease in their level as compared to the indicator
observed 3 months after treatment; the obtained indicator was
significantly higher as compared to their basal level. Three
months after treatment, AST level reached the level of the
control group in patients of Group IIA and Group IIB, while
in Group IIC, this indicator was 16.7% higher as compared
to its initial value (p<0.05). ALT level was 40.0% higher as
compared to its initial value (p<0.05) in patients of Group IIC.
Moreover, in patients of Group IIA and Group IIB, the differ-
ence between GGTP level 6 months after treatment and the
basal level was +0.55 and +1.16, while in patients of Group
IIC, this indicator increased by 5.0, respectively.
Thus, the obtained results necessitated the development
of differentiated approaches to long-term APT depending on
the effectiveness of achieving sufficient control of platelet
haemostasis. In particular, there was determined the possi-
bility of using long-term monotherapy with acetylsalicylic
acid, liver function monitoring, the inclusion of an appropri-
ate scheme of hepatoprotective therapy and the correction of
antiplatelet treatment 3 and 6 months after its administration
if necessary in order to treat patients with stable CHD and
co-existent NAFLD in stage of steatosis.
3. Conclusions
1. The use of long-term differentiation APT in patients
with stable CHD and co-existent NAFLD in stage of
steatosis provides an effective monitoring of platelet
haemostasis thereby reducing long-term cardiovascular
risk.
2. To treat patients with stable CHD and co-existent NAFLD
in stage of steatosis, it is reasonable to use a differenti-
ated approach to APT, dynamic liver function monitor-
ing and to include appropriate hepatoprotective drugs,
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Figure 1. Algorithm of antiplatelet and hepatoprotective differentiation therapy in patients with stable CHD and co-existent
NAFLD in stage of steatosis depending on changes in the functional state of the liver on the background of treatment.
Notes: LE – liver enzymes (AST ALT, GGTP); - monitoring of liver function by serum levels of LE as compared to the basal
level; + - sufficient control of platelet haemostasis; - - insufficient control of platelet haemostasis.
if necessary.
3. The developed concept of differentiation treatment of
patients with CHD and co-existent NAFLD in stage
of steatosis envisages the need for monitoring the indi-
cators of platelet haemostasis and liver function every
three months after the administration of APT with the
possibility of its intensification and the inclusion of hep-
atoprotective drugs according to the appropriate scheme
depending on the increase in liver enzyme levels.
4. Prospects for further research
Further research should be directed at the development of new
differentiated approaches to combination treatment of patients
with CHD and co-existent NAFLD in stage of non-alcoholic
steatohepatitis.
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Table 1. Dynamics of platelet haemostasis in patients with stable CHD and co-existent NAFLD in stage of steatosis, (M±m)
Indicator, Control Patients with stable CHD and co-existent NAFLD in stage of steatosis (n=72)
units of group Basal Group I (n=38) Group II (n=34)
measurement (n=20) level 3 months 6 months after treatment 3 months 6 months after treatment
after
treatment
subgroup
A (n=23)
subgroup
B (n=15)
after
treatment
subgroup
A (n=13)
subgroup
B (n=11)
subgroup
C (n=10)
A
D
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in
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eg
at
io
n
Aggregation
time, sec
15.70 ±
1.84
10.21 ±
0.74*
12.03 ±
0.64* §
15.25 ±
0.73 §¶
12.93 ±
0.46* §
11.96 ±
0.72* §
15.01 ±
0.38 §¶
12.64 ±
0.42* §
12.17 ±
0.39* §
∆ +5.04 +2.72 +4.80 +2.43 +1.96
Aggregation
rate,
%/sec
14.13 ±
0.30
19.64 ±
0.40*
16.92 ±
0.40* §
13.98 ±
0.26 §¶
16.73 ±
0.26* §
16.18 ±
0.32* §
14.27 ±
0.26 §¶
15.82 ±
0.34* §
15.94 ±
0.38* §
∆ -5.66 -2.91 -5.37 -3.82 -3.70
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degree, %
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0.49* §
21.36 ±
0.48 §¶
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0.36* §
23.87 ±
0.47* §
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count,
K/mcL
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11.34* §
305.37 ±
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∆ -112.04 -89.93 -105.08 -84.81 -71.9
Von Wille-
brand
factor, %
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7.19
259.49 ±
10.57*
218.57 ±
8.46* §
188.42 ±
6.53 §¶
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8.42* §
224.63 ±
10.80* §
192.31 ±
6.67§¶
208.35 ±
8.56* §
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Notes: * – a reliable difference as compared to the control group (p<0.05); § – a reliable difference as compared to the basal level (p<0.05);
¶ – a reliable difference as compared to the indicator 3 months after treatment (p<0.05); ∆ – the difference between the indicator observed 6
months after treatment and the basal level.
Table 2. Dynamics of platelet haemostasis in patients with stable CHD and co-existent NAFLD in stage of steatosis, (M±m)
Indicator Control Patients with stable CHD and co-existent NAFLD in stage of steatosis (n=72)
units of group Basal Group I (n=38) Group II (n=34)
measurement (n=20) level 3 months 6 months after treatment 3 months 6 months after treatment
after
treatment
subgroup
A (n=23)
subgroup
B (n=15)
after
treatment
subgroup
A (n=13)
subgroup
B (n=11)
subgroup
C (n=10)
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mmol/L
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Notes: * – a reliable difference as compared to the control group (p<0.05); § – a reliable difference as compared to the basal level (p<0.05);
¶ – a reliable difference as compared to the indicator 3 months after treatment (p<0.05); ∆ – difference between the indicator observed 6
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